M&A / Deals Biogen pens $1bn deal to buy immunology biotech RayThera PharmaphorumBiogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion.Immunology & InflammationRead full story pharminent June 18, 2026 (Last updated: June 18, 2026) Pharmaphorum Biogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion. Immunology & Inflammation Read full story Post navigation Previous: Previous PostNext: LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
